Human regulatory macrophages as a cell-based medicinal product

Current Opinion in Organ Transplantation

Volumn 17, Issue 1, 2012, Pages 48-54

  Hutchinson, James A ^a   Riquelme, Paloma ^a   Geissler, Edward K ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

cell therapy; immunosuppression; regulatory macrophage

Indexed keywords

AZATHIOPRINE; GAMMA INTERFERON; TACROLIMUS;

CELL MIGRATION; GRAFT SURVIVAL; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MACROPHAGE; MONOTHERAPY; ORGAN TRANSPLANTATION; PHENOTYPE; QUALITY CONTROL; REVIEW;

ANIMALS; CLINICAL TRIALS AS TOPIC; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; MACROPHAGES; ORGAN TRANSPLANTATION; TRANSPLANTATION TOLERANCE; TRANSPLANTATION, HOMOLOGOUS;

EID: 84856088094     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e32834ee64a     Document Type: Review

References (40)

1. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004; 351:2715-2729. (Pubitemid 39665325)
2. Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004; 4:378-383. (Pubitemid 38282293)
3. Orlando G, Hematti P, Stratta RJ, et al. Clinical operational tolerance after renal transplantation: Current status and future challenges. Ann Surg 2010; 252:915-928.
4. Hanaway MJ, Woodle ES, Mulgaonkar S, et al. Alemtuzumab induction in renal transplantation. N Engl J Med 2011; 364:1909-1919.
5. 3+ regulatory T cells increase de novo in kidney transplant patients after immunodepletion with Campath-1H. Am J Transplant 2008; 8:793-802. (Pubitemid 351347746)
6. Kawai T, Cosimi AB, Sachs DH. Preclinical and clinical studies on the induction of renal allograft tolerance through transient mixed chimerism. Curr Opin Organ Transplant 2011; 16:366-371.
7. Hutchinson JA, Riquelme P, Sawitzki B, et al. Cutting edge: Immunological consequences and trafficking of human regulatory macrophages administered to renal transplant recipients. J Immunol 2011; 187:2072-2078.
8. Bluestone JA. Mechanisms of tolerance. Immunol Rev 2011; 241:5-19.
9. Leslie M. Immunology. Regulatory T cells get their chance to shine. Science 2011; 332:1020-1021.
10. Turka LA, Wood K, Bluestone JA. Bringing transplantation tolerance into the clinic: lessons from the ITN and RISET for the Establishment of Tolerance consortia. Curr Opin Organ Transplant 2010; 15:441-448.
11. 25+ regulatory T cells approach the clinic. Cytotherapy 2008; 10:655-656.
12. Battaglia M, Roncarolo MG. Immune intervention with T regulatory cells: Past lessons and future perspectives for type 1 diabetes. Semin Immunol 2011; 23:182-194.
13. Popp FC, Fillenberg B, Eggenhofer E, et al. Safety and feasibility of third-party multipotent adult progenitor cells for immunomodulation therapy after liver transplantation: A phase I study (MISOT-I). J Transl Med 2011; 9:124.
14. Hutchinson JA, Riquelme P, Geissler EK, Fä ndrich F. Human regulatory macrophages. Methods Mol Biol 2011; 677:181-192.
15. Belardelli F, Rizza P, Moretti F, et al. Translational research on advanced therapies. Ann Ist Super Sanita 2011; 47:72-78.
16. Use of unregulated stem-cell based medicinal products. Lancet 2010; 376:514.
17. Tobin JJ, Walsh G, Medicinal product regulatory affairs. Weinheim: Wiley- VCH Verlag GmbH; 2008. A comprehensive introduction to medical product regulatory affairs in the EU and USA.
18. Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use.
19. Regulation (EC) No 1394/2007 of the European Parliament and of the Council on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004.
20. Directive 2004/23/EC of the European Parliament and of the Council of 31 of March 2004 on setting standards of quality and safety for the donation, procurement, testing, processing, preservation, storage and distribution of human tissues and cells.
21. EMEA/CHMP guideline on human cell-based medicinal products (EMEA/ CHMP/410869/2006). Guidelines stating the position of the EMA on the essential characteristics of human cell-based medicinal products.
22. Wolpert L, Technology is not science. In The unnatural nature of science. London: Faber and Faber Limited; 1992. pp. 25-34.
23. Fä ndrich F, Lin X, Chai GX, et al. Preimplantation-stage stem cells induce long-term allogeneic graft acceptance without supplementary host conditioning. Nat Med 2002; 8:171-178. (Pubitemid 34155129)
24. Hutchinson JA, Riquelme P, Brem-Exner BG, et al. Transplant acceptanceinducing cells as an immune-conditioning therapy in renal transplantation. Transpl Int 2008; 21:728-741.
25. Hutchinson JA, Brem-Exner BG, Riquelme P, et al. A cell-based approach to the minimization of immunosuppression in renal transplantation. Transpl Int 2008; 21:742-754.
26. Hutchinson JA, Roelen D, Riquelme P, et al. Preoperative treatment of a presensitized kidney transplant recipient with donor-derived transplant acceptance- inducing cells. Transpl Int 2008; 21:808-813.
27. Hutchinson JA, Govert F, Riquelme P, et al. Administration of donor-derived transplant acceptance-inducing cells to the recipients of renal transplants from deceased donors is technically feasible. Clin Transplant 2009; 23:140-145.
28. Riquelme P, Govert F, Geissler EK, et al. Human transplant acceptanceinducing cells suppress mitogen-stimulated T cell proliferation. Transpl Immunol 2009; 21:162-165.
29. Brem-Exner BG, Sattler C, Hutchinson JA, et al. Macrophages driven to a novel state of activation have anti-inflammatory properties in mice. J Immunol 2008; 180:335-349.
30. Fä ndrich F. Cell therapy approaches aiming at minimization of immunosuppression in solid organ transplantation. Curr Opin Organ Transplant 2010 [Epub ahead of print].
31. Ph.Eur. Text 5.1.6: Alternative methods for control of microbiological quality (01/2008:50106) and General Method 2.6.27: Microbiological control of cellular products.
32. Munn DH, Zhou M, Attwood JT, et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 1998; 281:1191-1193. (Pubitemid 28406294)
33. Cobbold SP, Adams E, Farquhar CA, et al. Infectious tolerance via the consumption of essential amino acids and mTOR signaling. Proc Natl Acad Sci U S A 2009; 106:12055-12060.
34. EMEA/CHMP guideline on potency testing of cell-based immunotherapy medicinal products for the treatment of cancer (CHMP/BWP/271475/06).
35. Warnecke G, Hutchinson JA, Riquelme P, et al. Postoperative intravenous infusion of donor-derived transplant acceptance-inducing cells as an adjunct immunosuppressive therapy in a porcine pulmonary allograft model. Transpl Int 2009; 22:332-341.
36. Crozat K, Guiton R, Guilliams M, et al. Comparative genomics as a tool to reveal functional equivalences between human and mouse dendritic cell subsets. Immunol Rev 2010; 234:177-198.
37. Nadig SN, Wieckiewicz J, Wu DC, et al. In vivo prevention of transplant arteriosclerosis by ex vivo-expanded human regulatory T cells. Nat Med 2010; 16:809-813.
38. Andreesen R, Scheibenbogen C, Brugger W, et al. A new approach to adoptive immunotherapy of cancer using tumor cytotoxic macrophages grown from peripheral blood monocytes. Cancer Detect Prev 1991; 15:413-421.
39. Marienhagen J, Hennemann B, Andreesen R, Eilles C. 111In-oxine labelling of tumour-cytotoxic macrophages generated in vitro from circulating blood monocytes: An in vitro evaluation. Nucl Med Commun 1995; 16:357-361.
40. Sagoo P, Perucha E, Sawitzki B, et al. Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans. J Clin Invest 2010; 120:1848-1861.